Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study.
Hermione C PriceMatthias BlüherRudolf PragerTra-Mi PhanBrian Larsen ThorstedBernd Schultesnull nullPublished in: Diabetes, obesity & metabolism (2018)
In real-world practice, after 6 months and at a moderate dose, IDegLira resulted in substantial reductions in HbA1c and body weight, with a reduced risk of hypoglycaemia.